Tzu Chi Medical Journal
Volume 21, Issue 4 , Pages 277-284, December 2009

Intravesical Botulinum Toxin Injection for Overactive Bladder—What We Can Learn From Previous Clinical Trials

  • Hann-Chorng Kuo

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Urology, Buddhist Tzu Chi General Hospital, 707, Section 3, Chung-Yang Road, Hualien, Taiwan

Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan

Received 22 September 2009; received in revised form 15 October 2009; accepted 17 October 2009.

Article Outline

Abstract 

Intravesical botulinum toxin A (BoNT-A) injection is effective in treating overactive bladder (OAB) and detrusor overactivity (DO)-induced incontinence refractory to antimuscarinic treatment. In the past 5 years, there have been several clinical trials using BoNT-A targeting OAB and idiopathic DO (IDO), and the therapeutic results are promising. Recent investigations have shown that urothelial dysfunction and abnormality of sensory receptor expression or transmitter release in the suburothelial nerves might contribute to OAB refractory to antimuscarinics. Intravesical BoNT-A treatment to inhibit abnormal receptor expression or transmitter release in the sensory nerve terminals in the suburothelial space has shown to have a good therapeutic effect on OAB. Intradetrusor or suburothelial BoNT-A injections, with small or large doses of BoNT-A in the bladder body or bladder base, can achieve satisfactory results. However, BoNT-A impairs detrusor contractility and causes a large postvoid residual (PVR) urine volume after injection in some patients. This adverse effect induces acute urinary retention and it is difficult to empty the bladder in the early postoperative period. Urinary tract infections can occur in patients with a large PVR. Although adverse effects may not influence the therapeutic outcome, they might prohibit wide application of BoNT-A in the treatment of refractory OAB. Patients with a high risk of a large PVR or urinary retention should be taught clean intermittent catheterization. Analysis of patient characteristics and urodynamic variables has shown that patients who are elderly, have low detrusor contractility at baseline, and have chronic medical diseases are at risk of adverse effects. Therefore, careful adjustment of the dose, appropriate injection site and correct patient selection is mandatory to achieve satisfactory results with intravesical BoNT-A therapy.

Keywords:  Adverse event , Botulinum toxin , Intravesical treatment , Overactive bladder , Urodynamics

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Abrams P , Kelleher CJ , Kerr LA , Rogers RG . Overactive bladder significantly affects quality of life . Am J Manag Care . 2000;6(Suppl 11):S580–S590
  2. Irwin DE , Milsom I , Kopp Z , Abrams P , Cardozo L . Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries . BJU Int . 2006;97:96–100
  3. Yoshimura N . Lower urinary tract symptoms (LUTS) and bladder afferent activity . Neurourol Urodyn . 2007;26(Suppl 6):908–913
  4. Chapple CR . Muscarinic receptor antagonist in the treatment of overactive bladder . Urology . 2000;55(Suppl 5A):33–50
  5. Dong M , Yeh F , Tepp WH , et al.   SV2 is the protein receptor for botulinum neurotoxin A . Science . 2006;312:592–596
  6. Dykstra DD , Sidi AA , Scott AB , Pagel JM , Goldish GD . Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients . J Urol . 1988;139:919–922
  7. Schurch B , Stohrer M , Kramer G , Schmid DM , Gaul G , Hauri D . Botulinum-A toxin for treating detrusor hyper-reflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results . J Urol . 2000;164:692–697
  8. Reitz A , Stohrer M , Kramer G , et al.   European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity . Eur Urol . 2004;45:510–515
  9. Aoki KR , Guyer B . Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions . Eur J Neurol . 2001;8(Suppl 5):21–29
  10. Apostolidis A , Popat R , Yiangou Y , et al.   Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of Botulinum toxin for human detrusor overactivity . J Urol . 2005;174:977–982
  11. Yiangou Y , Facer P , Ford A , et al.   Capsaicin receptor VR1 and ATP-gated ion channel P2X3 in human urinary bladder . BJU Int . 2001;87:774–779
  12. Avelino A , Cruz F . TRPVI (vanilloid receptor) in the urinary tract: expression, function and clinical applications . Naunyn Schmiedebergs Arch Pharmacol . 2006;373:287–299
  13. Aoki KR . Evidence for antinociceptive activity of botulinum toxin type A in pain management . Headache . 2003;43(Suppl 1):S9–15
  14. Cui M , Aoki KR . Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model . Cephalalgia . 2000;20:414–418
  15. Kuo HC . Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents . Urology . 2004;63:868–872
  16. Kessler TM , Danuser H , Schumacher M , Studer UE , Burkhard FC . Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? . Neurourol Urodyn . 2005;24:231–236
  17. Werner M , Schmid DM , Schussler B . Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study . Am J Obstet Gynecol . 2005;192:1735–1740
  18. Kuo HC . Clinical effects of suburothelial injection of botulinum A toxin in patients with non-neurogenic detrusor overactivity refractory to anticholinergics . Urology . 2005;66:94–98
  19. Schulte-Baukloh H , Weiss C , Stolze T , Sturzebecher B , Knispel HH . Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction . Urology . 2005;66:82–87
  20. Schulte-Baukloh H , Weiss C , Stolze T , et al.   Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction . Eur Urol . 2005;48:984–990
  21. Ghei M , Maraj BH , Miller R , et al.   Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial . J Urol . 2005;174:1873–1877
  22. Rajkumar GN , Small DR , Mustafa AW , Conn G . A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity . BJU Int . 2005;96:848–852
  23. Popat R , Apostolidis A , Kalsi V , Gonzales G , Fowler CJ , Dasgupta P . A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin . J Urol . 2005;174:984–989
  24. Kuo HC . Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? . Urology . 2006;68:993–998
  25. Schmid DM , Sauermann P , Werner M , et al.   Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics . J Urol . 2006;176:177–185
  26. Lucioni A , Rapp DE , Gong EM , Fedunok P , Bales GT . Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection . Can J Urol . 2006;13:3291–3295
  27. Hoebeke P , Caestecker KD , Walle JV , et al.   The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor . J Urol . 2006;176:328–331
  28. Kalsi V , Apostolidis A , Popat R , Gonzales G , Fowler CJ , Dasgupta P . Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes . Eur Urol . 2006;49:528–535
  29. Hirst GR , Watkins AJ , Guerrero K , et al.   Botulinum toxin B is not an effective treatment of refractory overactive bladder . Urology . 2007;69:69–73
  30. Ghalayini IF , Al-Ghazo MA . Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction . Neurourol Urodyn . 2007;26:531–536
  31. Sahai A , Khan MS , Dasgupta P . Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial . J Urol . 2007;177:2231–2236
  32. Kuo HC . Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity . J Urol . 2007;178:1359–1363
  33. Jeffery S , Fynes M , Lee F , Wang K , Williams L , Morley R . Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity . BJU Int . 2007;100:1302–1306
  34. Karsenty G , Elzayat E , Delapparent T , St-Denis B , Liemileux MC , Corcus J . Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux . J Urol . 2007;177:1011–1014
  35. Kalsi V , Apostolidis A , Gonzales G , Elneil S , Dasgupta P , Fowler CJ . Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity . Eur Urol . 2008;54:181–187
  36. Kuschel S , Werner M , Schmid DM , Faust E , Schuessler B . Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up . Int Urogynecol J Pelvic Floor Dysfunct . 2008;19:905–909
  37. Brubaker L , Richter HE , Visco A , et al.   Refractory idiopathic urge urinary incontinence and botulinum A injection . J Urol . 2008;180:217–222
  38. White WM , Pickens RB , Doggweiller R , Klein FA . Short-term efficacy of botulinum toxin A for refractory overactive bladder in the elderly population . J Urol . 2008;180:2522–2526
  39. Khan S , Kessler TM , Apostolidis A , et al.   What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type A injection . J Urol . 2009;181:1773–1778
  40. Cohen BL , Barboglio P , Rodriguez D , Gousse AE . Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units . Neurourol Urodyn . 2009;28:205–208
  41. Sahai A , Sangster P , Kalsi V , Khan MS , Fowler CJ , Dasgupta P . Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable . BJU Int . 2009;103:630–634
  42. Flynn MK , Amundsen CL , Perevich M , Liu F , Webster GD . Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder . J Urol . 2009;181:2608–2615
  43. Kessler TM , Khan S , Panicker J , Rosen A , Elneil S , Fowler CJ . Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life . Obstet Gynecol . 2009;113:1046–1051
  44. Andersson KE , Chapple CR , Cardozo L , et al.   Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence . Curr Opin Urol . 2009;19:380–394
  45. Apostolidis A , Dasgupta P , Denys P , et al.   Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report . Eur Urol . 2009;55:100–120
  46. Kuo HC . Measurement of detrusor wall thickness in women with overactive bladder by transvaginal and transabdominal sonography . Int Urogynecol J Pelvic Floor Dysfunct . 2009;20:1293–1299
  47. Mehnert U , Boy S , Schmid M , et al.   A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging . World J Urol . 2009;27:397–403
  48. Zermann DH , Ishigooka M , Schubert J , Schmidt RA . Trigonum and bladder base injection of botulinum toxin A (BTX) in patients with severe urgency-frequency-syndrome refractory to conservative medical treatment and electrical stimulation . Neurourol Urodyn . 2001;20:412–413
  49. Mascarenhas F , Cocuzza M , Gomes CM , Leão N . Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients . Neurourol Urodyn . 2008;27:311–314
  50. Shaban AM , Drake MJ . Botulinum toxin treatment for over-active bladder: risk of urinary retention . Curr Urol Rep . 2008;9:445–451

PII: S1016-3190(09)60056-2

doi:10.1016/S1016-3190(09)60056-2

Tzu Chi Medical Journal
Volume 21, Issue 4 , Pages 277-284, December 2009

Article Tools